APA (7th ed.) Citation

Ma, L., Yang, W., Zhou, X., Ye, L., Xu, G., Hu, C., . . . Tong, H. (2023). Safety and Efficacy of Selinexor Sequential Azacytidine in Newly Diagnosed Patients with Myelodysplastic Syndromes EB1 or EB2: A Single-Center, Single-Arm, Phase Ib/II Trial. Blood, 142(Supplement 1), 1856. https://doi.org/10.1182/blood-2023-183101

Chicago Style (17th ed.) Citation

Ma, Liya, et al. "Safety and Efficacy of Selinexor Sequential Azacytidine in Newly Diagnosed Patients with Myelodysplastic Syndromes EB1 or EB2: A Single-Center, Single-Arm, Phase Ib/II Trial." Blood 142, no. Supplement 1 (2023): 1856. https://doi.org/10.1182/blood-2023-183101.

MLA (9th ed.) Citation

Ma, Liya, et al. "Safety and Efficacy of Selinexor Sequential Azacytidine in Newly Diagnosed Patients with Myelodysplastic Syndromes EB1 or EB2: A Single-Center, Single-Arm, Phase Ib/II Trial." Blood, vol. 142, no. Supplement 1, 2023, p. 1856, https://doi.org/10.1182/blood-2023-183101.